Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGWBO:HPHA 10 Gross Margin % is 91.25% as of May. 2026, which is 85% above its 10-year median of 49.25. GuruFocus rates WBO:HPHA with a GF Score™ of 10/100 and a GF Value™ of €0.94 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 732 Biotechnology companies, Heidelberg Pharma AG ranks better than 73.91% on this metric.
The historical rank and industry rank for Heidelberg Pharma AG's Gross Margin % or its related term are showing as below:
WBO:HPHA'
s Gross Margin % Range Over the Past 10 Years
Min: -169.26 Med: 49.25 Max: 81.33
Current: 81.27
During the past 13 years, the highestGross Margin % of Heidelberg Pharma AG was 81.33%. The lowest was -169.26%. And the median was 49.25%.
WBO:HPHA's Gross Margin % is ranked better than 73.91% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs WBO:HPHA: 81.27
Heidelberg Pharma AG had a gross margin of 91.25% for the quarter that ended in May. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Heidelberg Pharma AG was 0.00% per year.
Heidelberg Pharma AG (WBO:HPHA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Heidelberg Pharma AG had a gross margin of 91.25% for the quarter that ended in May. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Heidelberg Pharma AG Gross Margin % Related Terms
Heidelberg Pharma AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:HPHA vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Heidelberg Pharma AG (WBO:HPHA) has a Gross Margin % of 91.25% as of May. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Heidelberg Pharma AG and its competitors. This is 85% above median its historical median of 49.25. According to the industry distribution chart, Heidelberg Pharma AG ranks #191 out of 732 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Heidelberg Pharma AG's Gross Margin % too high?
Heidelberg Pharma AG's current Gross Margin % of 91.25% is 85% above median its 10-year median of 49.25. The Biotechnology industry median Gross Margin % is 60.91. Heidelberg Pharma AG's value of 91.25% is 49.8% above this industry median. Based on the distribution chart, Heidelberg Pharma AG ranks #191 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Heidelberg Pharma AG has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #191 out of 732 companies for Gross Margin %. This puts Heidelberg Pharma AG in the upper half of its industry. The industry median Gross Margin % is 60.91. Heidelberg Pharma AG's value of 91.25% is 49.8% above this benchmark. While the company's 10-year median is 49.25 vs. the industry median of 60.91, Heidelberg Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heidelberg Pharma AG's current Gross Margin % of 91.25% is 49.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Gross Margin % is 91.25%, which is 85% above median its own 10-year median of 49.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.94, compared to a current price of €2.55 — trading 171.3% above its estimated fair value. The current Gross Margin % is 91.25%, which is 85% above median its 10-year median of 49.25 and 49.8% above the Biotechnology industry median of 60.91. Heidelberg Pharma AG's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current Gross Margin % is 91.25% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be overvalued.
The current stock price of €2.55 is trading 171.3% above its estimated GF Value™ of €0.94.
GuruFocus considers Heidelberg Pharma AG to be Significantly Overvalued.
Key valuation signals for WBO:HPHA:
Gross Margin %: 91.25% (85% above median its 10-year median of 49.25)
GF Value™: €0.94 vs. price of €2.55 (171.3% above fair value)
Industry Position: 49.8% above the Biotechnology median (#191 of 732)
No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score
Get the complete analysis for WBO:HPHA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HPHA has been successfully added to your 
